Dr RR Baliga's "Got Knowledge Doc" Podkast

Thrilled to see a major step forward in dengue prevention! 🦟💊 A new NEJM study reports that daily mosnodenvir, a first-in-class antiviral targeting the NS3–NS4B interaction, significantly reduced DENV-3 viral load and prevented infection in a controlled human challenge model. 📉🧬 It's early, but the results offer real hope for a long-awaited oral dengue prophylaxis—with encouraging safety, strong PK, and dose-dependent efficacy. 🚀🌍 Exciting moment for global infectious-disease innovation and antiviral development. 🙌✨

Delighted to share a concise update on the latest NEJM review of Long QT Syndrome 🫀📘 — a masterful synthesis by Schwartz & Crotti that reframes how we recognize risk, personalize therapy, and prevent sudden death in this genetically mediated disorder. The piece highlights ion-channel biology, gene-specific triggers, the impact of modifier genes, and the effectiveness of a tiered therapeutic approach including beta-blockers, mexiletine, and left cardiac sympathetic denervation ⚡️🧬🛡️. For clinicians and trainees, it's a compelling reminder that precise diagnosis, careful QT interpretation, and yearly risk reassessment remain central to saving lives. Highly recommended reading for anyone involved in cardiac electrophysiology or inherited arrhythmia care 📚✨

🧠✨ Leibniz: Harmony, Logic, and the Birth of the Digital Mind Celebrating Gottfried Wilhelm Leibniz — the mathematician-philosopher who co-created calculus, invented binary arithmetic, and envisioned a world stitched together by pre-established harmony. His Monadology reads like proto-systems theory, and his binary system is the quiet ancestor of every computer we use today. For clinicians and scientists, his legacy whispers: 🔹 Seek the sufficient reason behind every pattern 🔹 Value multiple perspectives — every "monad" reflects a different truth 🔹 Build harmonies across disciplines, data streams, and patient narratives 🧩💡 From metaphysics to modern computing, he reminds us that insight deepens when logic meets wonder.

🧬 New insights into autism: A 2025 JCI Viewpoint highlights how hundreds of genes, polygenic risk, and specific environmental factors converge during fetal brain development to shape autism likelihood. 🧠 Early biomarkers—from infant MRI and ERPs to machine-learning models using EHR data—are accelerating earlier, more tailored interventions. 🌱 Advances in gene therapy, IGF-1 pathways, and proteomics offer emerging therapeutic possibilities. 🤝 Centering autistic voices remains essential as precision approaches evolve.

🔍 Peripheral Neuropathy: What Clinicians Should Know 🧠⚡ Peripheral neuropathy affects ~1% of adults worldwide, with diabetes accounting for more than half of all cases. The JAMA review highlights why length-dependent patterns dominate, how metabolic stress injures long axons first, and why sensory symptoms outpace motor loss. Evidence-based evaluation still begins with glucose testing, vitamin B12 with methylmalonic acid, and serum protein electrophoresis. First-line therapies for neuropathic pain — gabapentin, pregabalin, duloxetine, and tricyclics — offer meaningful but often incomplete relief, reminding us that prevention and risk factor modification remain central. A clear, elegant synthesis of mechanisms, diagnostics, and management — essential reading for anyone caring for patients with numbness, tingling, or burning feet. 👣✨

New NEJM insights on asymptomatic carotid stenosis 🧠🔍 The CREST-2 trials offer a landmark update: intensive medical therapy remains the cornerstone, while carotid stenting shows selective benefit when performed by expert operators. Endarterectomy, however, provides no significant advantage over modern medical management. With stricter blood-pressure and LDL targets, plus expanding use of PCSK9 inhibitors, the future of stroke prevention is increasingly precision-driven, medically optimized, and patient-centered. 💊📉✨ A thoughtful read for all involved in vascular care, cerebrovascular prevention, and clinical decision-making. 📘🫀

The new Lancet Series on ultra-processed foods offers a striking insight: as UPFs rise globally, traditional whole-food diets decline—bringing nutrient imbalance, overeating, toxic exposures, and hyper-palatable formulations that quietly reshape health trajectories. 🍔➡️⚠️ Across more than 100 prospective studies and multiple trials, higher UPF intake consistently links to obesity, type 2 diabetes, cardiovascular disease, kidney disease, depression, and higher all-cause mortality. 📉🩺 The message is clear: reducing UPF consumption isn't a wellness trend—it's a public health imperative. Evidence-based policies and renewed investment in minimally processed, culturally rooted food systems are urgently needed. 🌱🔬🌏 #UltraProcessedFoods #PublicHealth #Nutrition #ChronicDisease #LancetSeries

Home-delivered DASH-patterned groceries paired with dietitian counseling meaningfully lowered blood pressure and LDL cholesterol among Black adults living in food deserts 🥗📉—as demonstrated in the GoFresh randomized trial (JAMA). An accompanying editorial highlights why future "food-as-medicine" programs must prioritize underconsumed, health-promoting foods and align with modern evidence favoring higher-fat DASH/Mediterranean patterns 🌱🫒. A powerful reminder: the right groceries can be therapeutic.

🩺 New insights in hemodialysis care. A major New England Journal of Medicine study reports that daily supplementation with long-chain omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) led to a 43% reduction in serious cardiovascular events among adults receiving maintenance hemodialysis. 🐟💙 In a population where traditional cardioprotective therapies often fall short, these findings open a fresh path for investigation — and perhaps, future practice. 📉🔬 A confirmatory trial will be essential, but the signal is compelling. 🌅

🚀 A milestone moment in lipid therapeutics! The new JAMA trial on the oral PCSK9 inhibitor Enlicitide reports a ~60% reduction in LDL-C, with parallel decreases in ApoB and Lp(a)—all on top of maximally tolerated statin therapy. For individuals with heterozygous familial hypercholesterolemia (HeFH)—where reaching LDL targets remains a persistent challenge—this represents a major advance. An oral agent matching the potency of injectable PCSK9 inhibitors could reshape adherence, access, and long-term ASCVD prevention. 🌉💊 Safety was comparable to placebo, and effects were rapid, robust, and sustained to 52 weeks. The ongoing CORALreef Outcomes trial will determine its impact on major cardiovascular events. 🔬❤️ Innovation in lipid lowering is accelerating—and patient-centered options are expanding. #JAMA #LipidManagement #HeFH #CardiovascularHealth #PCSK9 #Enlicitide #Prevention 🌟

☕ DECAF Trial insight! A new JAMA study shows that daily caffeinated coffee may lower recurrence of atrial fibrillation compared with abstinence. Patients drinking ~1 cup/day had 47% recurrence vs 64% with abstinence (HR 0.61, p=0.01) 📉💓 No major safety concerns—challenging long-held beliefs that coffee is proarrhythmic. 💡Takeaway: For many patients with AF, enjoying their morning brew may be both safe and possibly beneficial. #AtrialFibrillation #Cardiology #JAMA #ClinicalTrials #HeartHealth ☕💓📊

🚨 New insights from The Lancet 🚨 A major individual-patient-data meta-analysis (6 RCTs, 8,836 patients) shows that complete revascularisation in acute myocardial infarction significantly reduces cardiovascular death, all-cause mortality, and recurrent MI. 💓📉 Benefits were consistent across age, sex, STEMI/NSTEMI, and lesion characteristics — strengthening the case for a more comprehensive approach beyond the culprit lesion alone. 🔬🩺 A powerful reminder: treating the whole heart saves more lives. ❤️✨

🧬 New NEJM data on Olezarsen! In patients with severe hypertriglyceridemia, monthly RNA-targeted therapy delivered major triglyceride reductions (−62% to −72%) and a significant drop in acute pancreatitis risk (rate ratio 0.15). ✨ Improvements extended to ApoC-III, remnant cholesterol, and non-HDL cholesterol, with consistent benefits across both CORE-TIMI trials. 💡 A promising step forward in precision lipid therapy and pancreatitis prevention.

📘 New Evidence from NEJM In a large meta-analysis of 17,801 patients with preserved LVEF after MI, beta-blockers did not reduce death, recurrent MI, or heart failure. Event rates were low, and outcomes were similar with or without therapy. 🫀📊 This clarifies practice for a growing post-MI population with LVEF ≥50%—precision matters more than tradition. 🎯 Full study: New England Journal of Medicine (2025). #Cardiology 💙 #ClinicalEvidence #MI #HeartHealth

📢 ADAPT AF-DES Trial — A Safer Path Forward! In patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation, NOAC monotherapy delivered striking benefits over combination therapy. ✅ Lower net adverse clinical events ✅ Marked reduction in major/CRNM bleeding ✅ Similar ischemic protection A beautifully simple strategy with meaningful impact. Published in NEJM (2025). 💊🛡️📉💓

🌊 OCEAN Trial offers fresh insight into antithrombotic therapy after successful AF ablation. In 1284 patients followed for 3 years, event rates were remarkably low 🌟. Rivaroxaban did not show superiority over aspirin for preventing stroke, systemic embolism, or covert embolic events, while bleeding risk was higher with anticoagulation. 🧠 96% had no new infarcts on MRI at follow-up. Published in NEJM (2025) — a valuable contribution to nuanced AF post-ablation care.

🧠 John Locke: Experience • Liberty • Toleration Born a physician-philosopher, Locke championed empiricism — the idea that knowledge begins with experience, not dogma. His tabula rasa shaped modern psychology, while his Two Treatises of Government defined rights, consent, and freedom that echo through modern democracies. For clinicians, his legacy reminds us to: 🔹 Trust observation and evidence over authority 🔹 Respect patient autonomy and informed consent 🔹 Foster pluralism and toleration in care His vision of reason and tolerance remains medicine's quiet ally. 🕊️📜💬 Observation. Reflection. Compassion.

🚀 VESALIUS-CV delivers powerful evidence: in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19%, with LDL-C lowered to a median of 45 mg/dL. 💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events. 🫀 Strong science. Clear signal. A new chapter in preventive cardiology. #Cardiology #LDL #Prevention #VESALIUSCV

🫀 Septic Shock, Refined at the Fingertips ⏱️ A powerful new JAMA (2025) trial brings us one step closer to truly personalized resuscitation. The ANDROMEDA-SHOCK-2 study shows that targeting capillary refill time (CRT) — a simple bedside sign — can shorten time on organ support vs usual care, without increasing mortality. Key insight: Sometimes the most elegant solutions are low-tech, high-touch, and right at the bedside. 🧠 Precision 🤚 Physiology 💡 Pragmatism #Sepsis #CriticalCare #PersonalizedMedicine #JAMA #Hemodynamics #ICU #Shock

🚨 SOFA-2 arrives — a thoughtful evolution in critical care scoring 🧠🫁🫀 After nearly 30 years, the SOFA score has been modernized using data from >3.3 million ICU patients across 9 countries. The updated SOFA-2 incorporates contemporary respiratory and cardiovascular supports (HFNC, NIPPV, vasopressors, ECMO) and refines thresholds while preserving simplicity and bedside usability. A meaningful step forward in describing organ dysfunction — with room for future biologically grounded refinement. 📖 Published in JAMA

SOFA-2 is here — a major advance in assessing organ dysfunction in critical illness 🧠🫁❤️ Three decades after the original SOFA score, this updated framework reflects modern ICU practice — integrating contemporary organ support (ventilation, vasopressors, RRT), delirium recognition, and global feasibility across resource settings 🌍📊 Validated in 3.3M+ ICU patients across 9 countries — a remarkable effort in global critical care science 🏥📈 A powerful step forward in our shared language of severity and recovery. 🔗 JAMA Network Open, 2025

💔 Peripartum Cardiomyopathy: When a Mother's Heart Fights for Two Peripartum cardiomyopathy is a leading yet often missed cause of maternal morbidity and mortality—striking late in pregnancy or months postpartum. Early suspicion, timely echo, and guideline-directed therapy save lives. 🩺 🧠 Bromocriptine, careful anticoagulation, and multidisciplinary care are reshaping outcomes, but global disparities persist. 🌍 Let's amplify awareness, strengthen systems, and protect mothers everywhere. 🤝❤️ #HeartFailure #MaternalHealth #Cardiology #GlobalHealth #PPCM

Rethinking "default lines" in the ICU 🧠🚑 A landmark NEJM trial shows that in patients with shock, deferring arterial catheterization and using automated cuff monitoring was noninferior for 28-day mortality — and reduced catheter-related complications. A gentle reminder: not every sick patient needs a needle to be well cared for. Precision isn't only invasive — sometimes it's thoughtful, measured, humane. 🌿💡 #CriticalCare #ICU #NEJM #Shock #Hemodynamics #PatientSafety

🌙 Bright Nights, Higher Heart Risk ❤️‍🩹 New findings in JAMA Network Open highlight that greater exposure to artificial light at night is associated with significantly increased risks of coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, and stroke — independent of sleep duration, lifestyle factors, and genetics. 💡 Clinical takeaway: Protecting circadian rhythms is cardiovascular prevention. Darker nights = healthier hearts. 🛌 Simple steps: blackout curtains, limit screens before bed, use warm/dim evening lighting. #Cardiology #JAMANetworkOpen #CircadianHealth #SleepMedicine #PrecisionPrevention #PublicHealth

The immune clock starts earlier than we think ⏳🧬 A landmark Nature study shows that immune aging begins quietly in midlife — decades before clinical frailty. Using >16M single-cell profiles and longitudinal vaccine responses, researchers found: • Stable, early transcriptional drift in naïve & memory T cells • A subtle TH2 shift that may weaken antiviral antibody quality • Reduced IgG class-switching to repeat flu antigens (e.g., B/Phuket) • No acceleration from CMV infection despite compositional shifts The message? Immune aging is gradual, not abrupt — and midlife may be the window for intervention. Precision immunology will increasingly mean precision geroscience.

🫀 TAVR or SAVR? The 7-Year Truth New 7-year results from the PARTNER-3 trial (NEJM) show that in low-risk patients with severe symptomatic aortic stenosis, TAVR holds pace with surgery — delivering comparable survival, stroke rates, rehospitalization, valve durability, and quality-of-life outcomes. 🔎 Highlights • Composite events: 34.6% (TAVR) vs 37.2% (SAVR) • Mortality: 19.5% vs 16.8% • Valve failure: 6.9% vs 7.3% • Aortic gradients remain low in both groups 💡 Clinical rhythm: less AF with TAVR; more pacemakers and paravalvular leak. This study reinforces a simple truth: in the right low-risk patient, TAVR is not just less invasive — it's durable. #Cardiology #StructuralHeart #AorticStenosis #TAVR #SAVR #NEJM

🌿 Spinoza: Reason, Nature, Freedom Today's deck explores Baruch Spinoza — the quietly revolutionary Dutch philosopher who shaped rationalism, modern biblical criticism, and secular democracy. He saw God = Nature, championed intellectual freedom, and argued that understanding our emotions transforms them — not far from cognitive-behavioral ideas we use in modern medicine. His reminder feels timely: human flourishing grows where inquiry is free, passions are understood, and systems support dignity + reason. 🧠🔍💬 Clarity is liberation.

A new era for complex mitral regurgitation. The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER. A third pathway for mitral disease is emerging—one built on precision access, valve-in-valve durability planning, and advancing patient selection. Innovation meeting clinical need. 🚀🫀📈

🧬 Can we rejuvenate the aging immune system? A remarkable Nature Biotechnology study shows that a rare population of periostin-positive mesenchymal niche cells can rebuild the adult thymus, recruit new T-cell progenitors, and restore immune responses after injury. By harnessing CCL19-expressing stromal support, the authors demonstrate a path toward immune renewal in aging, cancer therapy recovery, and HSCT survivors. ✨ A glimpse of regenerative immunology's future: Rebuild. Recruit. Rejuvenate. #Immunology #Aging #RegenerativeMedicine #Thymus #TCells #PrecisionMedicine #ImmuneHealth

🩺🎗️ Cardio-Oncology Insight: Not Every Breast Cancer Survivor Needs a Cardiologist As breast cancer survivorship grows, understanding who truly benefits from long-term cardiac follow-up becomes essential. An important editorial in JAMA Oncology underscores a key principle: risk-stratified care, not reflex surveillance. 👩‍⚕️🔍 Age and traditional cardiovascular risk factors outweigh treatment exposure (including anthracyclines and ERBB2 therapy) in driving late heart failure and cardiomyopathy risk among survivors . 🏥💡 Most survivors can be safely followed by primary care clinicians focused on: • Controlling blood pressure, diabetes, lipids • Encouraging physical activity & healthy weight • Monitoring symptoms and functional status ❤️📊 Select high-risk patients — older age, multiple CV risk factors, or treatment-related dysfunction — benefit most from targeted cardio-oncology evaluation. This editorial reminds us that precision survivorship means personalizing cardiac follow-up, emphasizing prevention, equity, and collaboration between oncology, cardiology, and primary care. 🌱 Goal: Survivors who not only live longer — but live well. #CardioOncology #BreastCancer #Survivorship #HeartFailurePrevention #PrecisionMedicine #PrimaryCare #JAMAOncology #CancerCare #CardioOnc #PopulationHealth #AcademicMedicine

🧬 Can we rejuvenate the aging immune system? A new Nature Aging trial suggests we might be closer than we thought. In 50 healthy adults aged 45–70, urolithin A—a mitophagy activator—improved immune fitness over just 28 days: ✅ ↑ naïve CD8⁺ T cells ✅ ↓ exhaustion markers (TOX) ✅ ↑ mitochondrial biogenesis (PGC-1α) ✅ ↑ fatty-acid oxidation capacity ✅ ↑ NK cell and monocyte function ✅ ↑ bacterial phagocytosis 💊 Well-tolerated with minimal adverse events 🔬 This builds on compelling translational work linking mitochondrial quality control to immunosenescence and "inflammaging." A reminder that metabolism and immunity are deeply intertwined—and that targeted interventions may help preserve immune resilience across the lifespan. 🧠 Aging isn't just years lived. It's biology modulated. #LongevityScience #Immunology #HealthyAging #Mitochondria #ClinicalResearch #TranslationalScience #Geroscience #ImmuneHealth #NatureAging

🫀 Personalizing DAPT: When "One Size Fits All" Fails 🕊️💊 The HOST-BR trial in The Lancet offers an important clinical lesson: Bleeding risk should guide antiplatelet duration after PCI — not habit, not inertia. 🔍 Key insight In ARC-HBR patients, 1-month DAPT was not non-inferior to 3 months In non-HBR patients, 3-month DAPT was non-inferior to 12 months and reduced bleeding 🧠 Clinical takeaway ➡️ Ultra-short (1-mo) DAPT is risky in high-bleeding-risk patients ➡️ Short (3-mo) DAPT is safe and bleeding-sparing in lower-risk patients 🔧 Precision medicine in action: Stratify → Tailor → Protect 📎 HOST-BR | The Lancet (2025) A beautiful reminder that medicine advances when we match therapy to physiology — not the other way around. 🌟 "Do no harm" is evolving… now it means do no unnecessary bleeding. #Cardiology #InterventionalCardiology #PrecisionMedicine #DAPT #PCI #BleedingRisk #Lancet

🚨 New Pharmacotherapy for Obstructive Sleep Apnoea 🌙💊 In a landmark Phase 2 trial published in The Lancet, sultiame— a carbonic anhydrase inhibitor—showed dose-dependent reduction in AHI and improved nocturnal oxygenation in adults with moderate–severe OSA. 💡 Key insights: • 298 participants across 5 European countries • 200 mg daily delivered the best efficacy-to-tolerability balance • Benefits most notable in sleepy phenotypes (ESS >10) • Mild, dose-related paraesthesia most common AE 🔬 A promising step toward precision sleep medicine and pharmacologic options for patients who struggle with CPAP. 🌬️ Better breathing by night → brighter cognition by day. 📖 Lancet, 2025 — FLOW Study (Randerath et al.)

📢 New Study Alert 🩺💊 In JAMA Internal Medicine, a national analysis reveals that using the PREVENT risk calculator (vs Pooled Cohort Equations) dramatically reduces the number of U.S. adults aged 40–59 eligible for aspirin in primary prevention of cardiovascular disease. Among 7.6 million current aspirin users, >96% wouldn't qualify by PREVENT 🤯. Time to rethink our calculators and consider deprescribing where net benefit is questionable. 📰 Read more: https://jamanetwork.com/journals/jamainternmed/fullarticle/10.1001/jamainternmed.2025.5049

🧠 TACSI Trial in NEJM (Sep 2025) challenges the status quo on dual antiplatelet therapy after CABG for ACS! 👨‍⚕️ 2201 patients across 5 Nordic countries 💊 Ticagrelor + Aspirin ≠ better outcomes vs Aspirin alone 📉 No reduction in death, MI, stroke, or revascularization 🩸 But bleeding (4.9% vs 2.0%) & dyspnea (18.2% vs 6.4%) increased 📚 Guidelines may need rethinking. 📖 Jeppsson A et al. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2508026 #TACSI #Cardiology #CABG #DAPT #ACS #NEJM #PrecisionMedicine #RCT #BleedingRisk #ClinicalTrials

🧪 NEO-MINDSET Trial 🇧🇷 published in NEJM asks: Can we safely drop aspirin early after PCI in acute coronary syndromes (ACS)? 💊 Monotherapy with ticagrelor/prasugrel reduced bleeding 🩸 but increased early ischemic events 💥 vs dual antiplatelet therapy (DAPT). ❗ Noninferiority for major adverse cardiovascular events was not met. 🔍 DAPT still stands tall in early post-PCI ACS care. Kudos to the Brazilian team for a landmark RCT! 📖 NEJM 2025 | doi: 10.1056/NEJMoa2507980 #NEOMINDSET #PCI #ACS #cardiotwitter #RCT #DAPT #P2Y12 #Bleeding #NEJM #PrecisionMedicine #InterventionalCardiology

🚨 New in NEJM — The ALASCCA Trial 🧬 Low-dose aspirin (160 mg/day) reduced colorectal cancer recurrence in patients with PIK3CA, PIK3R1, or PTEN mutations 🎯 ✅ 3-year recurrence: 7.7% (aspirin) vs 14–17% (placebo) ✅ Group A HR: 0.49 | Group B HR: 0.42 ✅ NNT as low as 6 in stage III rectal cancer 💥 ⚠️ Slight increase in adverse events 🧠 Editorial calls it a new standard of care: 🔬 Genotype early + 💊 Start aspirin early = 📉 Lower recurrence 📖 Read both the trial and editorial in NEJM, Sept 2025 #ColorectalCancer #PrecisionOncology #Aspirin #PIK3CA #NEJM #OncologyTrials #Genomics #AdjuvantTherapy #ALASCCA #ClinicalTrials

💡 TARGET-FIRST trial (NEJM, Aug 2025) shows that in low-risk AMI patients post-PCI with complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy is noninferior to dual antiplatelet therapy—with 54% fewer bleeding events 🩸🛑💊 ⚖️ A modern, patient-tailored antiplatelet strategy—backed by potent P2Y12 inhibitors and smart selection—might just be the new norm in contemporary cardiology 🫀 📘 New England Journal of Medicine 🔗 https://doi.org/10.1056/NEJMoa2508808 #Cardiology #DAPT #PrecisionMedicine #NEJM #TARGETFIRST

💡 "Cogito, ergo sum" — I think, therefore I am. René Descartes laid the foundation of modern Western philosophy and scientific reasoning, linking algebra to geometry, and mind to body. 🧠📐 His legacy reminds healthcare professionals to unite reason with compassion — science with soul. ❤️⚕️

💊🫀 Aspirin in the Crosshairs? The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation. 📉 Adding aspirin led to: • ↑ Ischemic events (HR 1.53; P=0.02) • ↑ Mortality (HR 1.72; P=0.01) • ↑ Major bleeding (HR 3.35; P) 🧠 Takeaway: More isn't always better. In high-risk CCS, aspirin may harm more than help. 📚 Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 #Cardiology #Antiplatelet #NEJM #PrecisionMedicine #AQUATICTrial

🧠💥 Could lead poisoning have helped shape human evolution? A bold new hypothesis suggests that Homo sapiens may have survived while Neanderthals and Denisovans vanished—thanks to genetic defenses against environmental lead. 🧬 By analyzing fossil teeth 🦷 and testing brain organoids 🧪, researchers found that ancient lead exposure disrupted key language-related genes (like FOXP2)—but not in modern human variants. 👣 Sometimes, evolution turns adversity into advantage. 📖 Published in Science (Oct 2025): "Did lead poisoning help drive human evolution?" 🔗 doi:10.1126/science.aed1022 #Evolution #Neuroscience #Anthropology #Genetics #FOXP2 #NOVA1 #LeadPoisoning #Paleoanthropology #Science 🦴🧬

🚨 New in Nature 🧬: Groundbreaking study reveals how HMGN1, a dosage-sensitive epigenetic regulator on chromosome 21, reprograms atrioventricular cardiomyocytes into a ventricular fate—driving congenital heart defects in Down syndrome 💔🫀. Using hiPSCs, single-cell RNA sequencing, and a CRISPRa CROP-seq screen, researchers pinpoint HMGN1 as a causal gene. Strikingly, reducing its dosage in a trisomy 21 mouse model reversed ventricular septal defects (VSDs) 🔧🐭. This is a model for dissecting aneuploidy-associated disease using human cells + in vivo rescue. Epigenetics meets cardiogenesis in real time. Don't miss this paradigm-shifting work! 📖 DOI: 10.1038/s41586-025-09593-9 #DownSyndrome #Cardiology #Epigenetics #CRISPR #scRNAseq #HMGN1 #CongenitalHeartDefects #StemCells #Nature #GeneDosage #PrecisionMedicine

🚭 Lung Cancer in Nonsmokers – a hidden epidemic affecting up to 20% of global cases 🌍. Unlike tobacco-related disease, this form often strikes younger, female, and Asian populations, with EGFR and ALK mutations driving tumors 🔬. Despite low mutation burden and no smoking history, these patients benefit immensely from targeted therapies like osimertinib and lorlatinib 🎯. Yet, there's no USPSTF recommendation for screening in this group 😔. We must push for awareness, early detection, and precision approaches 🧬. As the review in JAMA (2025) shows, no smoke doesn't mean no risk. 🔗 doi:10.1001/jama.2025.17695 #LungCancer #PrecisionMedicine #Oncology #PublicHealth #JAMA

👟 Just 2 Days Can Make a Difference! 🧓📉 In a large cohort of 13,547 older women (mean age 72), walking ≥4,000 steps/day on even 1–2 days/week was linked to a 26% lower mortality and 27% lower cardiovascular disease risk 💥. Those walking ≥3 days/week had even greater benefits! 📉 Higher step thresholds (up to 7,000/day) showed further mortality reduction—but step volume, not frequency, drove outcomes. 🧠 Message? There's no "perfect pattern"—even weekend walks count. 💡 Time to rethink activity guidelines and empower aging with steps. 📄 Hamaya R et al, Br J Sports Med, 2025. 🔗 https://doi.org/10.1136/bjsports-2025-110311 #Longevity #CardioHealth #WomenInMedicine #PublicHealth #WeekendWarrior #HealthyAging #ExactitudeStudy #StepsToHealth #CVD #ExerciseIsMedicine

🧓 Aging skin, fading flow. This 2025 Nature study uncovers how dermal capillary-associated macrophages (CAMs) decline with age—preceding microvascular dysfunction and impaired blood flow. 🧬 Using intravital imaging and macrophage fate mapping in mice (and validating in humans!), the authors reveal that CAMs are not replenished unless triggered by injury or CSF1. 🛠️ Fascinatingly, local CSF1–Fc therapy restored CAMs and rejuvenated perfusion in aged skin. A compelling case for targeting tissue-resident immunity! 🩸 📖 doi:10.1038/s41586-025-09639-y

🫀📉 Published in The Lancet (Oct 22, 2025): SELECT trial investigators report that semaglutide reduced MACE by 20% in patients with obesity but without diabetes—independent of weight loss. Waist circumference, not weight, tracked with outcomes, yet explained only 33% of the benefit. This landmark analysis redefines GLP-1RAs as disease-modifying agents, not just weight-loss drugs. 👉 Read here: https://doi.org/10.1016/S0140-6736(25)01375-3 #SELECTTrial #Semaglutide #Cardiovascular #Obesity #GLP1RA #TheLancet

Hair Loss in Women" (The New England Journal of Medicine 2025; DOI 10.1056/NEJMcp2412146) 📄, and it's a must‑listen for anyone in clinical practice or research. The piece highlights that female‑pattern hair loss increases with age and is closely tied to hormonal status, and that treatments span from topical 5% minoxidil or low‑dose oral minoxidil to anti‑androgens and adjunctive non‑drug approaches.

🔍 New in The Lancet! A massive network meta-analysis of 94 RCTs (105,435 patients) reveals that antidepressants impact far more than mood 🧠—they alter weight ⚖️, glucose 🩸, BP 💓, lipids 🧬, and liver enzymes 🧪. Agomelatine 🌙 may lower weight, while nortriptyline 📈 raises heart rate. Time to rethink side-effect profiles when prescribing! 📚 Pills, Pressure, and Physiology — catch the full summary & clinical pearls now! #Antidepressants #CardiometabolicHealth #Depression #PrecisionMedicine #Lancet 🧠💊⚖️

🧬 Her Genes, His Risk, Our Mind 💡 New insights from Thomas et al., Nature Communications (2025) — summarized beautifully by Na Cai in Nature News & Views. Women carry a heavier polygenic burden for major depressive disorder (MDD), with ~6,000 female-specific variants and stronger genetic links to metabolic traits like BMI and metabolic syndrome. 🧠 Men show a unique X-chromosome signal (IL1RAPL1), pointing to sex-specific biology in depression. Precision psychiatry must evolve to be sex-aware, data-driven, and equitable. ⚕️ #Genomics #Depression #PrecisionMedicine #SexDifferences #Neurogenetics

🦷🫀 New Findings Linking Oral Health to Heart Attacks! 🧬🧫 Groundbreaking research in JAHA reveals that viridans streptococci, common oral bacteria, form biofilms in atherosclerotic plaques that evade immune detection. These stealthy invaders trigger innate and adaptive immune responses, correlating with plaque rupture, myocardial infarction, and sudden cardiac death. The study combines autopsy data, endarterectomy samples, immunohistochemistry, TLR activation assays, and genome-wide expression to uncover this bacterial-inflammation nexus. 🧠 Could dental hygiene be the next frontier in cardiovascular prevention? 📖 Karhunen et al. JAHA. 2025;14:e041521 🔗 #Cardiology #Immunology #OralHealth #Atherosclerosis #Biofilm #PrecisionMedicine #JAHA #DentalHealth #SuddenCardiacDeath #MultiOmics #CHD #ViridansStreptococci #PlaqueRupture #InnateImmunity #AdaptiveImmunity #TLR2 #NFkB #Streptococcus #MI #Endarterectomy